ANDERSON SPICKARD, M.D.; WILLIAM T. BUTLER, M.D.; VINCENT ANDRIOLE, M.D.; JOHN P. UTZ, M.D., F.A.C.P.
Cryptococcal meningitis is the most frequent cause of mycotic meningitis in man, accounting for about 10 per cent of the 300 to 400 fatal mycoses reported annually in the United States (1). The actual incidence of this type of mycotic meningitis cannot be determined accurately, but the number of case reports in the literature in recent years indicates that the disease is being recognized more frequently.
The discovery of amphotericin B by Gold, Stout, Pagano, and Donovick (2) was a significant scientific achievement, for it gave to clinicians a therapeutic agent useful in a wide variety of mycotic diseases, but
SPICKARD A, BUTLER WT, ANDRIOLE V, et al. The Improved Prognosis of Cryptococcal Meningitis with Amphotericin B Therapy. Ann Intern Med. 1963;58:66–83. doi: https://doi.org/10.7326/0003-4819-58-1-66
Download citation file:
Published: Ann Intern Med. 1963;58(1):66-83.
CNS Infections, Infectious Disease, Neurology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use